![Jean-Paul Renaud](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Jean-Paul Renaud is associated with two companies, NovAliX SAS and Urania Therapeutics SAS.
He was the Chief Scientific Officer at NovAliX SAS, which was founded in 2002.
At Urania Therapeutics SAS, he is the President, Director, and Chief Scientific Officer, and the company was founded in 2015.
Postes actifs de Jean-Paul Renaud
Sociétés | Poste | Début |
---|---|---|
Urania Therapeutics SAS
![]() Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Fondateur | 01/10/2015 |
Anciens postes connus de Jean-Paul Renaud
Sociétés | Poste | Fin |
---|---|---|
NovAliX SAS
![]() NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
NovAliX SAS
![]() NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Health Technology |
Urania Therapeutics SAS
![]() Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Health Technology |